Affimed (NASDAQ:AFMD) Sees Significant Decline in Short Interest

Affimed (NASDAQ:AFMD) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 742,900 shares, a decrease of 12.3% from the December 15th total of 846,900 shares. Based on an average daily volume of 291,200 shares, the short-interest ratio is currently 2.6 days. Approximately 5.7% of the company’s stock are sold short.

Affimed Stock Up 6.5 %

Shares of NASDAQ:AFMD opened at $1.15 on Friday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 1 year low of $1.03 and a 1 year high of $8.95. The stock’s fifty day moving average price is $2.05 and its 200-day moving average price is $3.35.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Wells Fargo & Company cut their target price on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Affimed in a research note on Tuesday, December 10th. Finally, Stifel Nicolaus cut their target price on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AFMD. Choreo LLC bought a new position in Affimed in the second quarter valued at about $54,000. Jane Street Group LLC bought a new position in shares of Affimed in the third quarter worth about $44,000. FMR LLC raised its stake in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC raised its stake in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares during the period. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.